CPT code 74221 denotes a double–contrast esophagram performed with high–density barium and an effervescent agent, including scout films and delayed imaging when performed. This radiologic procedure evaluates esophageal anatomy and mucosal detail and remains an important diagnostic option for dysphagia, reflux-related symptoms, and suspected structural lesions. Nationally, the code is relevant for imaging utilization, radiology workflow, and coverage determinations across major payers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The analysis addresses payer coverage patterns, coding and billing considerations, and clinical context for when a double–contrast esophagram is used versus alternative modalities.

Readers will find a concise overview of benchmarks for utilization and reimbursement (where available), common billing practices and modifiers relevant to the claim line, and the clinical scenarios that typically prompt use of this study. The publication also highlights policy considerations that affect prior authorization, site-of-service implications, and documentation elements that support medical necessity. Data not provided in the input are noted as unavailable; the report focuses on the clinical purpose, payer landscape, and billing context for CPT code 74221 at the national level.